Last reviewed · How we verify

NCT03415945

Left Ventricular Septal Pacing: Potential Application for Cardiac Resynchronization Therapy

Status unknown NA Last updated 12 February 2018
What this trial tests

NA trial testing Cardiac resynchronization therapy (CRT) in Heart Failure in 30 participants. Status unknown.

Timeline
23 November 2017
Primary endpoint
23 May 2019
23 May 2020

Quick facts

Lead sponsorMaastricht University Medical Center
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date23 November 2017
Primary completion23 May 2019
Estimated completion23 May 2020
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Maastricht University Medical Center

Who can join

18 and older, any sex, with Heart Failure or Cardiac Resynchronization Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In cardiac resynchronization therapy (CRT), biventricular pacing is performed by pacing the right ventricle (RV) and epicardium of the left ventricular (LV) postero-lateral wall. A significant proportion of apparently suitable patients fail to benefit from CRT. One of the problems of CRT is proper positioning and fixation of the LV pacing lead in the coronary vein. LV septal pacing may be a good alternative for BiV pacing in patients with an indication for CRT.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other Maastricht University Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03415945.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing